Last reviewed · How we verify

OXERVATE® 0.002% — Competitive Intelligence Brief

OXERVATE® 0.002% (OXERVATE® 0.002%) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant growth factor. Area: Ophthalmology.

marketed Recombinant growth factor Nerve growth factor receptor (TrkA, p75NTR) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

OXERVATE® 0.002% (OXERVATE® 0.002%) — Dompé Farmaceutici S.p.A. OXERVATE contains recombinant human nerve growth factor (rhNGF) that promotes corneal nerve regeneration and healing of neurotrophic keratopathy.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
OXERVATE® 0.002% TARGET OXERVATE® 0.002% Dompé Farmaceutici S.p.A marketed Recombinant growth factor Nerve growth factor receptor (TrkA, p75NTR)
Juvista (Avotermin) Juvista (Avotermin) Renovo phase 3 Recombinant growth factor TGF-β3 (Transforming Growth Factor Beta-3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant growth factor class)

  1. Dompé Farmaceutici S.p.A · 1 drug in this class
  2. Renovo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OXERVATE® 0.002% — Competitive Intelligence Brief. https://druglandscape.com/ci/oxervate-0-002. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: